Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

BACKGROUND: Neoadjuvant checkpoint inhibition (CPI) has recently demonstrated impressive outcomes in patients with stage 3 cutaneous melanoma. However, the safety, efficacy, and outcome of neoadjuvant CPI in patients with mucosal melanoma (MM) are not well studied as MM is a rare melanoma subtype. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Joel, Mattei, Jane, Tetzlaff, Michael, Williams, Michelle D., Davies, Michael A., Diab, Adi, Oliva, Isabella C. Glitza, McQuade, Jennifer, Patel, Sapna P., Tawbi, Hussein, Wong, Michael K., Fisher, Sarah B., Hanna, Ehab, Keung, Emily Z., Ross, Merrick, Weiser, Roi, Su, Shirley Y., Frumovitz, Michael, Meyer, Larissa A., Jazaeri, Amir, Pettaway, Curtis A., Guadagnolo, B. Ashleigh, Bishop, Andrew J., Mitra, Devarati, Farooqi, Ahsan, Bassett, Roland, Faria, Silvana, Nagarajan, Priyadharsini, Amaria, Rodabe N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618687/
https://www.ncbi.nlm.nih.gov/pubmed/36324592
http://dx.doi.org/10.3389/fonc.2022.1001150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618687/
https://www.ncbi.nlm.nih.gov/pubmed/36324592
http://dx.doi.org/10.3389/fonc.2022.1001150

Ejemplares similares